{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:26:48Z","timestamp":1792027608997,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CCF22-0064-PS ; R43-HL158409-01A1 ; R43-HL158409-01A1S1 ; R43-HL158409-01A1S2 ;"],"award-info":[{"award-number":["CCF22-0064-PS ; R43-HL158409-01A1 ; R43-HL158409-01A1S1 ; R43-HL158409-01A1S2 ;"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CCF22-0064-PS ; R43-HL158409-01A1 ; R43-HL158409-01A1S1 ; R43-HL158409-01A1S2 ;"],"award-info":[{"award-number":["CCF22-0064-PS ; R43-HL158409-01A1 ; R43-HL158409-01A1S1 ; R43-HL158409-01A1S2 ;"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CCF22-0064-PS ; R43-HL158409-01A1 ; R43-HL158409-01A1S1 ; R43-HL158409-01A1S2 ;"],"award-info":[{"award-number":["CCF22-0064-PS ; R43-HL158409-01A1 ; R43-HL158409-01A1S1 ; R43-HL158409-01A1S2 ;"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-025-03349-9","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:48:23Z","timestamp":1761659303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The PTP4A3 inhibitor KVX-053 reduces Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virulence, inflammation, and development of acute lung injury in K18-hACE2 mice"],"prefix":"10.1186","volume":"26","author":[{"given":"Ruben M. L.","family":"Colunga-Biancatelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel A.","family":"Solopov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin M.","family":"Woodson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving Coy","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Akhrymuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryna","family":"Akhrymuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany N.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah M.","family":"Ivester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tierney","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan E.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylene","family":"Kehn-Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Lazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Sharlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Catravas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"3349_CR1","unstructured":"Hopkins J. Coronavirus resoruce center. https:\/\/coronavirus.jhu.edu\/map.html"},{"issue":"12","key":"3349_CR2","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1111\/jeb.13896","volume":"34","author":"S Alizon","year":"2021","unstructured":"Alizon S, Sofonea MT. SARS-CoV-2 virulence evolution: avirulence theory, immunity and trade-offs. J Evol Biol. 2021;34(12):1867\u201377.","journal-title":"J Evol Biol"},{"issue":"1\u20132","key":"3349_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s42977-023-00159-2","volume":"74","author":"\u00c1 Kun","year":"2023","unstructured":"Kun \u00c1, et al. Do pathogens always evolve to be less virulent? The virulence-transmission trade-off in light of the COVID-19 pandemic. Biol Futura. 2023;74(1\u20132):69\u201380.","journal-title":"Biol Futura"},{"issue":"8","key":"3349_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Horby P, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693\u2013704.","journal-title":"N Engl J Med"},{"issue":"1","key":"3349_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"C Salama","year":"2021","unstructured":"Salama C, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20\u201330.","journal-title":"N Engl J Med"},{"issue":"7","key":"3349_CR6","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1093\/cid\/ciac724","volume":"78","author":"A Bhimraj","year":"2024","unstructured":"Bhimraj A, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19 (September 2022). Clin Infect Dis. 2024;78(7):e250\u2013349.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"3349_CR7","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.12998\/wjcc.v11.i10.2168","volume":"11","author":"J Sun","year":"2023","unstructured":"Sun J, et al. Clinical application of SARS-CoV-2 antibody detection and monoclonal antibody therapies against COVID-19. World J Clin Cases. 2023;11(10):2168\u201380.","journal-title":"World J Clin Cases"},{"issue":"2","key":"3349_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","volume":"21","author":"M Cox","year":"2023","unstructured":"Cox M, et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat Rev Microbiol. 2023;21(2):112\u201324.","journal-title":"Nat Rev Microbiol"},{"key":"3349_CR9","first-page":"100243","volume":"11","author":"\u00c1 Avezum","year":"2022","unstructured":"Avezum \u00c1, et al. Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE \u2013 Coalition V): a double-blind, multicentre, randomised, controlled trial. Lancet Reg Health\u2013Am. 2022;11:100243.","journal-title":"Lancet Reg Health\u2013Am"},{"issue":"1","key":"3349_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2258","volume":"32","author":"AM Kamel","year":"2022","unstructured":"Kamel AM, et al. Efficacy and safety of azithromycin in Covid-19 patients: a systematic review and meta-analysis of randomized clinical trials. Rev Med Virol. 2022;32(1):e2258.","journal-title":"Rev Med Virol"},{"issue":"10259","key":"3349_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","volume":"396","author":"PW Horby","year":"2020","unstructured":"Horby PW, et al. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345\u201352.","journal-title":"Lancet"},{"issue":"11","key":"3349_CR12","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.3201\/eid1011.040797_02","volume":"10","author":"JW LeDuc","year":"2004","unstructured":"LeDuc JW, Barry MA. SARS, the first pandemic of the 21st century. Emerg Infect Dis. 2004;10(11):e26.","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"3349_CR13","first-page":"264","volume":"32","author":"V Apostolopoulos","year":"2024","unstructured":"Apostolopoulos V, et al. MERS outbreak in riyadh: A current concern in Saudi Arabia. Infez Med. 2024;32(2):264\u20136.","journal-title":"Infez Med"},{"issue":"8","key":"3349_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727\u201333.","journal-title":"N Engl J Med"},{"issue":"3","key":"3349_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105924","volume":"55","author":"CC Lai","year":"2020","unstructured":"Lai CC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.","journal-title":"Int J Antimicrob Agents"},{"issue":"10223","key":"3349_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507\u201313.","journal-title":"Lancet"},{"issue":"1","key":"3349_CR17","first-page":"209","volume":"85","author":"AL Katzenstein","year":"1976","unstructured":"Katzenstein AL, Bloor CM, Leibow AA. Diffuse alveolar damage\u2013the role of oxygen, shock, and related factors. A review. Am J Pathol. 1976;85(1):209\u201328.","journal-title":"Am J Pathol"},{"issue":"7865","key":"3349_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41586-021-03569-1","volume":"595","author":"JC Melms","year":"2021","unstructured":"Melms JC, et al. A molecular single-cell lung atlas of lethal COVID-19. Nature. 2021;595(7865):114\u20139.","journal-title":"Nature"},{"issue":"7847","key":"3349_CR19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-020-03148-w","volume":"590","author":"RA Grant","year":"2021","unstructured":"Grant RA, et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021;590(7847):635\u201341.","journal-title":"Nature"},{"issue":"12","key":"3349_CR20","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1038\/s41590-023-01661-4","volume":"24","author":"N Huot","year":"2023","unstructured":"Huot N, et al. SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-\u03b3 and NK cells. Nat Immunol. 2023;24(12):2068\u201379.","journal-title":"Nat Immunol"},{"issue":"1","key":"3349_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41420-021-00428-w","volume":"7","author":"AC Ferreira","year":"2021","unstructured":"Ferreira AC, et al. SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes. Cell Death Discov. 2021;7(1):43.","journal-title":"Cell Death Discov"},{"issue":"8","key":"3349_CR22","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s41587-020-0602-4","volume":"38","author":"RL Chua","year":"2020","unstructured":"Chua RL, et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat Biotechnol. 2020;38(8):970\u20139.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"3349_CR23","doi-asserted-by":"publisher","first-page":"L477","DOI":"10.1152\/ajplung.00223.2021","volume":"321","author":"RML Colunga Biancatelli","year":"2021","unstructured":"Colunga Biancatelli RML, et al. The SARS-CoV-2 Spike protein subunit S1 induces COVID-19-like acute lung injury in \u039a18-hACE2 Transgenic mice and barrier dysfunction in human endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2021;321(2):L477\u201384.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"3349_CR24","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.124.002154","author":"PA Solopov","year":"2024","unstructured":"Solopov PA, et al. KVX-053, a protein tyrosine phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 spike protein subunit 1 - induced acute lung injury in mice. J Pharmacol Exp Ther. 2024. https:\/\/doi.org\/10.1124\/jpet.124.002154.","journal-title":"J Pharmacol Exp Ther"},{"key":"3349_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fasebj.2022.36.S1.R4649","volume":"36","author":"RML Colunga Biancatelli","year":"2022","unstructured":"Colunga Biancatelli RML, et al. A protein tyrosine phosphatase 4A3 (PTP4A3) inhibitor prevents and repairs pulmonary endothelial barrier dysfunction and ameliorates acute lung injury provoked by the SARS-CoV-2 Spike protein subunit 1 in k18-hACE2 Transgenic mice. FASEB J. 2022;36:1.","journal-title":"FASEB J"},{"key":"3349_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpet.2024.100045","author":"P Montuschi","year":"2025","unstructured":"Montuschi P, Adcock IM. Protein tyrosine phosphatase 4A3 inhibition: a new pharmacological strategy for acute lung injury? J Pharmacol Exp Ther. 2025. https:\/\/doi.org\/10.1016\/j.jpet.2024.100045.","journal-title":"J Pharmacol Exp Ther"},{"issue":"28","key":"3349_CR27","doi-asserted-by":"publisher","first-page":"21444","DOI":"10.1074\/jbc.M000453200","volume":"275","author":"Q Zeng","year":"2000","unstructured":"Zeng Q, et al. Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and \u2013 3 with the plasma membrane and the early endosome. J Biol Chem. 2000;275(28):21444\u201352.","journal-title":"J Biol Chem"},{"key":"3349_CR28","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.124.002110","author":"JS Lazo","year":"2024","unstructured":"Lazo JS, et al. Deletion of PTP4A3 phosphatase in high grade serous ovarian cancer cells decreases tumorigenicity and produces marked changes in intracellular signaling pathways and cytokine release. J Pharmacol Exp Ther. 2024. https:\/\/doi.org\/10.1124\/jpet.124.002110.","journal-title":"J Pharmacol Exp Ther"},{"key":"3349_CR29","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.122.001401","author":"SL John","year":"2023","unstructured":"John SL, et al. Disruption of ovarian cancer STAT3 and p38 signaling with a small molecule inhibitor of PTP4A3 phosphatase. J Pharmacol Exp Ther. 2023. https:\/\/doi.org\/10.1124\/jpet.122.001401.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"3349_CR30","doi-asserted-by":"publisher","first-page":"A4565","DOI":"10.1016\/j.chest.2023.07.2959","volume":"164","author":"LC Manuel","year":"2023","unstructured":"Manuel LC, Biancatelli R, et al. KVX-053, A PTP4A3 INHIBITOR, MODULATES THE ENDOCYTIC PATHWAY, EXTRACELLULAR VESICLE UPTAKE, ENDOTHELIAL BARRIER DYSFUNCTION, AND THE DEVELOPMENT OF ARDS IN VITRO AND IN VIVO. Chest. 2023;164(4):A4565\u20136.","journal-title":"Chest"},{"issue":"7865","key":"3349_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-021-03570-8","volume":"595","author":"TM Delorey","year":"2021","unstructured":"Delorey TM, et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature. 2021;595(7865):107\u201313.","journal-title":"Nature"},{"issue":"7","key":"3349_CR32","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3390\/biom11070969","volume":"11","author":"JS Lazo","year":"2021","unstructured":"Lazo JS, et al. Credentialing and pharmacologically targeting PTP4A3 phosphatase as a molecular target for ovarian cancer. Biomolecules. 2021;11(7):969.","journal-title":"Biomolecules"},{"issue":"5\u20136","key":"3349_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.vph.2009.12.009","volume":"52","author":"JD Catravas","year":"2010","unstructured":"Catravas JD, et al. Harvesting, identification and barrier function of human lung microvascular endothelial cells. Vascul Pharmacol. 2010;52(5\u20136):175\u201381.","journal-title":"Vascul Pharmacol"},{"key":"3349_CR34","doi-asserted-by":"publisher","DOI":"10.3791\/52065","author":"A Baer","year":"2014","unstructured":"Baer A, Kehn-Hall K. Viral concentration determination through plaque assays: using traditional and novel overlay systems. JoVE. 2014. https:\/\/doi.org\/10.3791\/52065.","journal-title":"JoVE"},{"issue":"5","key":"3349_CR35","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1165\/rcmb.2009-0210ST","volume":"44","author":"G Matute-Bello","year":"2011","unstructured":"Matute-Bello G, et al. An official American thoracic society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol. 2011;44(5):725\u201338.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"9","key":"3349_CR36","doi-asserted-by":"publisher","first-page":"8223","DOI":"10.18632\/oncotarget.23787","volume":"9","author":"KE McQueeney","year":"2018","unstructured":"McQueeney KE, et al. Targeting ovarian cancer and endothelium with an allosteric PTP4A3 phosphatase inhibitor. Oncotarget. 2018;9(9):8223\u201340.","journal-title":"Oncotarget"},{"issue":"4","key":"3349_CR37","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41592-022-01447-w","volume":"19","author":"H Chu","year":"2022","unstructured":"Chu H, Chan JF-W, Yuen K-Y. Animal models in SARS-CoV-2 research. Nat Methods. 2022;19(4):392\u20134.","journal-title":"Nat Methods"},{"issue":"1","key":"3349_CR38","doi-asserted-by":"publisher","first-page":"e0096421","DOI":"10.1128\/JVI.00964-21","volume":"96","author":"W Dong","year":"2022","unstructured":"Dong W, et al. The K18-Human ACE2 transgenic mouse model recapitulates non-severe and severe COVID-19 in response to an infectious dose of the SARS-CoV-2 virus. J Virol. 2022;96(1):e0096421.","journal-title":"J Virol"},{"key":"3349_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/biom14030342","author":"H Liu","year":"2024","unstructured":"Liu H, et al. Protein tyrosine phosphatase PRL-3: a key player in cancer signaling. Biomolecules. 2024. https:\/\/doi.org\/10.3390\/biom14030342.","journal-title":"Biomolecules"},{"issue":"6","key":"3349_CR40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.slasd.2023.02.001","volume":"28","author":"JS Lazo","year":"2023","unstructured":"Lazo JS, et al. An acute respiratory distress syndrome drug development collaboration stimulated by the Virginia drug discovery consortium. SLAS Discov. 2023;28(6):249\u201354.","journal-title":"SLAS Discov"},{"issue":"1\u20133","key":"3349_CR41","first-page":"181","volume":"565","author":"KA Kim","year":"2004","unstructured":"Kim KA, et al. Structure of human PRL-3, the phosphatase associated with cancer metastasis. FEBS Lett. 2004;565(1\u20133):181\u20137.","journal-title":"FEBS Lett"},{"issue":"18","key":"3349_CR42","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1158\/0008-5472.CAN-19-0343","volume":"79","author":"PSY Chong","year":"2019","unstructured":"Chong PSY, et al. IL6 promotes a STAT3-PRL3 feedforward loop via SHP2 repression in multiple myeloma. Cancer Res. 2019;79(18):4679.","journal-title":"Cancer Res"},{"issue":"1","key":"3349_CR43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.bbrc.2012.11.036","volume":"430","author":"S Lian","year":"2013","unstructured":"Lian S, et al. PRL-3 activates NF-\u03baB signaling pathway by interacting with RAP1. Biochem Biophys Res Commun. 2013;430(1):196\u2013201.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"3349_CR44","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1074\/jbc.M113.480038","volume":"289","author":"MW Zimmerman","year":"2014","unstructured":"Zimmerman MW, et al. Protein-tyrosine phosphatase 4A3 (PTP4A3) promotes vascular endothelial growth factor signaling and enables endothelial cell motility. J Biol Chem. 2014;289(9):5904\u201313.","journal-title":"J Biol Chem"},{"issue":"1","key":"3349_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1365-2958.2005.04822.x","volume":"58","author":"H Mart\u00edn","year":"2005","unstructured":"Mart\u00edn H, et al. Protein phosphatases in MAPK signalling: we keep learning from yeast. Mol Microbiol. 2005;58(1):6\u201316.","journal-title":"Mol Microbiol"},{"issue":"11","key":"3349_CR46","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1182\/blood.V110.11.671.671","volume":"110","author":"M Sebag","year":"2007","unstructured":"Sebag M, et al. PRL3 is a mediator of IL6\/STAT3 signaling and defines a population of multiple myeloma patients distinct from those that activate NFkB. Blood. 2007;110(11):671\u2013671.","journal-title":"Blood"},{"key":"3349_CR47","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.freeradbiomed.2021.10.015","volume":"177","author":"Y Shi","year":"2021","unstructured":"Shi Y, et al. PRL-3 dephosphorylates p38 MAPK to promote cell survival under stress. Free Radic Biol Med. 2021;177:72\u201387.","journal-title":"Free Radic Biol Med"},{"key":"3349_CR48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-2091-13-22","volume":"13","author":"W Tian","year":"2012","unstructured":"Tian W, et al. Phosphatase of regenerating liver-3 directly interacts with integrin \u03b21 and regulates its phosphorylation at tyrosine 783. BMC Biochem. 2012;13:22.","journal-title":"BMC Biochem"},{"issue":"1","key":"3349_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01038-3","volume":"7","author":"J Pan","year":"2022","unstructured":"Pan J, et al. Targeting protein phosphatases for the treatment of inflammation-related diseases: from signaling to therapy. Signal Transduct Target Ther. 2022;7(1):177.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3349_CR50","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1038\/s41598-019-39643-y","volume":"9","author":"L Duciel","year":"2019","unstructured":"Duciel L, et al. Protein tyrosine phosphatase 4A3 (PTP4A3\/PRL-3) promotes the aggressiveness of human uveal melanoma through dephosphorylation of CRMP2. Sci Rep. 2019;9(1):2990.","journal-title":"Sci Rep"},{"key":"3349_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2021.128167","volume":"46","author":"EJ Rastelli","year":"2021","unstructured":"Rastelli EJ, et al. Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors activating the ER stress pathway. Bioorg Med Chem Lett. 2021;46:128167.","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"3349_CR52","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1124\/jpet.119.262188","volume":"371","author":"JS Lazo","year":"2019","unstructured":"Lazo JS, et al. Next-generation cell-active inhibitors of the undrugged oncogenic PTP4A3 phosphatase. J Pharmacol Exp Ther. 2019;371(3):652\u201362.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"3349_CR53","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1124\/molpharm.120.000131","volume":"98","author":"MP Czub","year":"2020","unstructured":"Czub MP, et al. Structure of the complex of an iminopyridinedione protein tyrosine phosphatase 4A3 phosphatase inhibitor with human serum albumin. Mol Pharmacol. 2020;98(6):648\u201357.","journal-title":"Mol Pharmacol"},{"issue":"6","key":"3349_CR54","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.7150\/thno.79265","volume":"13","author":"PL Chia","year":"2023","unstructured":"Chia PL, et al. PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types. Theranostics. 2023;13(6):1876\u201391.","journal-title":"Theranostics"},{"issue":"3","key":"3349_CR55","doi-asserted-by":"publisher","first-page":"100022","DOI":"10.1124\/jpet.124.002154","volume":"392","author":"PA Solopov","year":"2025","unstructured":"Solopov PA, et al. KVX-053, a protein tyrosine phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 Spike protein subunit 1\u2013induced acute lung injury in mice. J Pharmacol Exp Ther. 2025;392(3):100022.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"3349_CR56","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1038\/s41467-025-59929-2","volume":"16","author":"KH Ang","year":"2025","unstructured":"Ang KH, et al. PRL3-zumab as an anti-angiogenic therapy in neovascular eye diseases. Nat Commun. 2025;16(1):4791.","journal-title":"Nat Commun"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03349-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-025-03349-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03349-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T01:03:13Z","timestamp":1761699793000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-025-03349-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3349"],"URL":"https:\/\/doi.org\/10.1186\/s12931-025-03349-9","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"John S. Lazo and Elizabeth R. Sharlow are co-inventors of U.S. Patent No. 10,308,663, which describes the chemical synthesis, composition of matter and use of KVX-053 for the treatment of cancer. A provisional US patent application entitled \u201cComposition and methods for treating\/preventing lung injury\u201d (Serial No. PCT\/US2022\/024927) and an European Union patent application (22788973.0) with the same title have been filed with John S. Lazo, Elizabeth R. Sharlow, John D. Catravas, Ruben M.L. Colunga Biancatelli, and Pavel A. Solopov being listed as co-inventors. John S. Lazo and Elizabeth Sharlow are co-founders of KeViRx, Inc, which has licensed the above-mentioned intellectual property from the University of Virginia, University of Pittsburgh, and Old Dominion University for further development.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"299"}}